Need professional-grade analysis? Visit stockanalysis.com
$59.18M
N/A
N/A
N/A
Tscan Therapeutics Inc (TCRX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.25, down 1.57% from the previous close.
Over the past year, TCRX has traded between a low of $0.90 and a high of $2.52. The stock has lost 27.3% over this period. It is currently 50.4% below its 52-week high.
Tscan Therapeutics Inc has a market capitalization of $59.18M.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Side-by-side comparison against top Healthcare peers.